Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 2/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 6/20 | 0.36 |
| ▸ | CDK8 | P49336 | 6/20 | 0.36 |
| ▸ | CDC7 | O00311 | 3/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19211726 | 0.98 | MKNK1 (0.38) | MKNK1KDM5CKDM4BKDM5BCCNC | |
| SCHEMBL288626 | 0.83 | KDM4E (0.44) | KDM5CKDM4BKDM5BCYP4F2CYP4A11 | |
| SCHEMBL30415076 | 0.77 | PTPN11 (0.46) | CCNCCDK8CYP4F2CYP4A11NUDT1 | |
| SCHEMBL5178575 | 0.77 | SYK (0.38) | NUDT1JMJD6 | |
| SCHEMBL2465021 | 0.75 | MKNK1 (0.42) | MKNK1CCNCCDK8CDC7NUDT1 | |
| SCHEMBL23675190 | 0.74 | CYP4A11 (0.36) | CYP4F2CYP4A11IKBKB | |
| SCHEMBL28327862 | 0.73 | CCNC (0.36) | MKNK1CCNCCDK8CDC7NUDT1 | |
| SCHEMBL985896 | 0.73 | GSK3B (0.46) | KDM5CKDM4BKDM5BCDC7CYP4F2 | |
| SCHEMBL23777269 | 0.73 | MKNK1 (0.33) | MKNK1CCNCCDK8CCNA2CDK2 | |
| SCHEMBL1219786 | 0.73 | EGLN1 (0.44) | KDM5BKDM4CKDM4EKDM6BKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728252-A1 | 4-AZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3507289-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2019-07-10 | — | — | EP | claimed |
| WO-2018042362-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-03-08 | — | — | WO | claimed |
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | MKNK1 1076/4885KDM5C 1375/4885KDM4B 2048/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | MKNK1 1076/4885KDM5C 1375/4885KDM4B 2048/4885 |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | MKNK1 4351/4885KDM5C 2146/4885KDM4B 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.